|
Name |
Peyronetide C
|
Molecular Formula | C24H26O7 | |
IUPAC Name* |
(8S)-8,10-dihydroxy-7-methoxy-3-[(E,4S)-4-methylhex-2-en-2-yl]-8-(2-oxopropyl)benzo[g]isochromene-1,9-dione
|
|
SMILES |
CC[C@H](C)/C=C(\C)/C1=CC2=CC3=C(C(=C2C(=O)O1)O)C(=O)[C@@](C(=C3)OC)(CC(=O)C)O
|
|
InChI |
InChI=1S/C24H26O7/c1-6-12(2)7-13(3)17-9-15-8-16-10-18(30-5)24(29,11-14(4)25)22(27)19(16)21(26)20(15)23(28)31-17/h7-10,12,26,29H,6,11H2,1-5H3/b13-7+/t12-,24-/m0/s1
|
|
InChIKey |
BSAREYHEZFOODA-XUHHNZALSA-N
|
|
Synonyms |
Peyronetide C
|
|
CAS | NA | |
PubChem CID | 146682609 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 426.5 | ALogp: | 4.5 |
HBD: | 2 | HBA: | 7 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 110.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 31 | QED Weighted: | 0.698 |
Caco-2 Permeability: | -4.744 | MDCK Permeability: | 0.00001420 |
Pgp-inhibitor: | 0.115 | Pgp-substrate: | 0.942 |
Human Intestinal Absorption (HIA): | 0.046 | 20% Bioavailability (F20%): | 0.035 |
30% Bioavailability (F30%): | 0.207 |
Blood-Brain-Barrier Penetration (BBB): | 0.052 | Plasma Protein Binding (PPB): | 92.80% |
Volume Distribution (VD): | 1.155 | Fu: | 6.74% |
CYP1A2-inhibitor: | 0.9 | CYP1A2-substrate: | 0.94 |
CYP2C19-inhibitor: | 0.577 | CYP2C19-substrate: | 0.547 |
CYP2C9-inhibitor: | 0.802 | CYP2C9-substrate: | 0.248 |
CYP2D6-inhibitor: | 0.124 | CYP2D6-substrate: | 0.15 |
CYP3A4-inhibitor: | 0.755 | CYP3A4-substrate: | 0.545 |
Clearance (CL): | 0.833 | Half-life (T1/2): | 0.105 |
hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.811 |
Drug-inuced Liver Injury (DILI): | 0.934 | AMES Toxicity: | 0.027 |
Rat Oral Acute Toxicity: | 0.257 | Maximum Recommended Daily Dose: | 0.949 |
Skin Sensitization: | 0.492 | Carcinogencity: | 0.922 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.022 |
Respiratory Toxicity: | 0.96 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004054 | 0.691 | D0O6KE | 0.273 | ||||
ENC004055 | 0.660 | D0WY9N | 0.267 | ||||
ENC005184 | 0.562 | D06FVX | 0.258 | ||||
ENC004057 | 0.422 | D0C1SF | 0.244 | ||||
ENC004148 | 0.356 | D0Q0PR | 0.239 | ||||
ENC004037 | 0.354 | D06GCK | 0.236 | ||||
ENC004632 | 0.351 | D07ESC | 0.232 | ||||
ENC004031 | 0.343 | D0N1FS | 0.228 | ||||
ENC004630 | 0.337 | D0T5XN | 0.228 | ||||
ENC004631 | 0.337 | D0QD1G | 0.228 |